Approval of teplizumab: implications for patients

Article Cell Biology

Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals

Emily K. Sims et al.

Summary: A single 14-day course of teplizumab treatment in high-risk individuals showed lasting effects on delaying type 1 diabetes diagnosis and improving beta cell function. Changes in CD8(+) T cell subsets indicated that partially exhausted effector cells were associated with clinical response to immune therapy. This trial demonstrated improvements in metabolic responses and diabetes delay with immune therapy.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical Care

Carla J. Greenbaum

Summary: The 2019 landmark report of a clinical trial showed that immune therapy could delay the onset of clinical type 1 diabetes in antibody-positive relatives by a median of 2 years, marking a significant achievement in the prevention of T1D. The next key step is to bring disease-modifying therapy for prevention or delay of T1D to clinical use from this point, by screening and monitoring relatives for T1D risk in the context of clinical care.

DIABETES (2021)

添加到收藏夹

Review Multidisciplinary Sciences

Immunotherapy: Building a bridge to a cure for type 1 diabetes

Jeffrey A. Bluestone et al.

Summary: Type 1 diabetes (T1D) is an autoimmune disease where T cells attack and destroy insulin-producing beta cells in the pancreas. While insulin therapy helps with symptoms, it does not cure the underlying disease or fully prevent complications. Current research is focused on developing immunological therapies to prevent and modify T1D.

SCIENCE (2021)

添加到收藏夹

Article Medicine, General & Internal